Inter-university Cape Heart Research Unit

Publications

Heart Research Unit and Hatter Institute

1. Opie L H. View point article: First line drugs in chronic stable effort angina - the case for newer longer-acting calcium channel blockers. Journal of the American College of Cardiology. 36: 1967-1971, 2000.
2. Opie LH. Adverse cardiovascular drug interactions. Current Problems in Cardiology, 25: 621-676, 2000.
3. Opie L H, Yusuf Y, Kubler W. Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies. Progress in Cardiovascular Disease, 43: 171-196, 2000.
4. Opie L H. Diuretic downsides - but in low doses they still seem among the best authenticated antihypertensives. Cardiovascular Drugs and Therapy, 14; 407 - 409, 2000.
5. Rayner BL, Opie LH, Davison JS. The aldosterone/renin ratio as a screening test for primary aldosteronism. South African Medical Journal, 90: 394-400, 2000.
6. Aitchison KA, Baxter GF, Awan MM, Smith RM, Yellon DM, Opie LH. Opposing effects on infarction of delta and kappa opioid receptor activation in the isolated rat heart: implications for ischemic preconditioning. Basic Research in Cardiology, 95: 1-10, 2000.
7. Sack MN, Smith RM, Opie LH. Tumour necrosis factor in myocardial hypertrophy and ischaemia - an anti-apoptotic perspective. Cardiovascular Research, 45: 688-695; 2000.
8. Awan MM, Makaula S, Forresti S, Sack MN, Opie LH. Mechanisms whereby glucose deprivation triggers metabolic preconditioning in the isolated rat heart. Molecular and Cellular Biochemistry. 211: 111-121, 2000.
9. Minners J, van den Bos EJ, Yellon DM, Schwalb H, Opie LH, Sack MN. Dinitrophenol, cyclosporin A, and trimetazidine modulate preconditioning in isolated rat heart: support for a mitochondrial role in cardioprotection. Cardiovascular Research, 47: 68-73, 2000.
10. Jonassen AK, Brar BK, Mjos OD, Sack MN, Latchman DS, Yellon DM. Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. Journal of Molecular and Cellular Cardiology, 32: 757-764, 2000.
11. Sack MN, Harrington LS, Jonassen AK, Mjos OD, Yellon DM. Coordinate regulation of metabolic enzyme encoding genes during cardiac development and following carvedilol therapy. Cardiovasular Drugs and Therapy, 14: 31-39, 2000.
12. Marshall D, Sack MN. Apoptosis: a pivotal event or an epiphenomenon in the pathophysiology of heart failure? Heart. 84: 355-356, 2000.
13. Bell P, Sack MN, Patel A, Opie LH, Yellon DM. Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. Journal of the American College of Cardiology. 36; 2000. in press.

Books

1. L H Opie (Author). Drugs for the Heart, 5th Edition. W B Saunders Company. Philadelphia, 2000 (426 pages).

Chapters in books

1. Kantor PF, Lopaschuk GD, Opie L H. Myocardial Energy Metabolism. In: Heart Physiology and Pathophysiology, 4th Edition. N Sperelakis, Y Kurachi, A Terzic, M V Cohen. Academic Press, San Diego, 2000. pp 543-543-569

Conference abstracts

1. Makaula S, Awan M, Lochner, Sack M, Opie L. H89, an inhibitor of PKA activity, administerd as a pretreatment or with subthreshold preconditioning promotes recovery of contractile function following ischemia/ reperfusion - a putative novel cardioprotective agent. South African Heart Association Meeting, Stellenbosch, November 2000.
2. Sack M. TNF? and myocardial protection. South African Heart Association Meeting, Stellenbosch, November 2000.
3. Ngumbela K. Cardiac medium-chain acyl CoA dehydrogenase is downregulated at pre- and post-translational levels following acute hypoxia in mice. South African Heart Association Meeting, Stellenbosch, November 2000.
4. Meiring J. TNF? promotes tolerance against ischemic damage in myocytes via NF?B activation - a putative autocrine/paracrine mediator of ischemic preconditioning. South African Heart Association Meeting, Stellenbosch, November 2000.
5. van den Bos EJ, Minners J, Opie LH, Sack MN. Trimetazidine abolishes ischemic and drug-induced preconditioning: does mitochondrial protection antagonize preconditioning-like cardioprotection? American Heart Association Meeting, New Orleans, November 2000. Circulation, 102 (Suppl II); II-269; 2000.
6. Makaula S, Awan M, Lochner, Sack M, Opie L. H89, an inhibitor of PKA activity, administerd as a pretreatment or with subthreshold preconditioning promotes recovery of contractile function following ischemia/ reperfusion - a putative novel cardioprotective agent. American Heart Association Meeting, New Orleans, November 2000. Circulation, 102 (Suppl II); II-269; 2000.
7. Minners J, Meiring JJ, van den Bos EJ, Opie LH, Sack MN. Inner mitochondrial membrane modulation in preconditioned myotubes: a putative role for mitochondrial homeostasis in enhanced tolerance to ischemia. American Heart Association Meeting, New Orleans, November 2000. Circulation, 102 (Suppl II); II-287; 2000.
8. Ngumbela K, Essop FM, McLeod C. Cardiac medium-chain acyl CoA dehydrogenase is downregulated at pre- and post-translational levels following acute hypoxia in mice. American Heart Association Meeting, New Orleans, November 2000. Circulation, 102 (Suppl II); II-344; 2000.

Lipid Clinic

Research papers and refereed articles

1. Berger GM, Marais AD. Diagnosis, Management and Prevention of the Common Dyslipidaemias in South Africa - Clinical Guideline, 2000. S Afr Med J 2000;90;164-178.
2. Marais AD. Dyslipidaemia in Diabetes Mellitus. Specialist Medicine 2000;22: 148-179.
3. Marais AD Will more aggressive lowering of plasma cholesterol concentrations better prevent coronary heart disease? Continuing Med Education 2000;18 (1):57,58 (Part I), 2000;18 (2): 168,169 (Part II), 2000;18 (3):252,253. (Part III).
4. Marais AD. South African Medicines Formulary 5th Ed. Eds Gibbon CJ, Barnes KI, Blockman M, Folb PI, McIlleron H, Orrell C, Robins AH. S Afr Med Assoc Health & Medical Publishing Group. 2000;150-156.
5. Clee SM, Bissada N, Miao F, Miao L, Marais AD, Henderson HE, Steures P, McManus B, LeBoeuf RC, Kastelein JJP, Hayden MR. Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. J Lipid Res. 2000;41:521-531.
6. Raal FJ, Pappu AS, Illingworth RI, Pilcher GJ, Marais AD, Firth JC, Kotze MJ, Heinonen TM, Black DM. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis 2000;150:421-428.
7. Marais AD. Therapeutic modulation of LDL particle size. Current Opinion Lipidology. 2000;11(6): 597-602.

Conference abstracts

1. Familial defective apolipoprotein B is of varied origin in South Africa. AD Marais1, S Jones1, JC Firth1, P Byrnes1, JK Ross1, M Moodie1, D Gaffney2. 1.Lipid Laboratory, UCT Health Science Faculty, Observatory SA and 2Pathological Biochemistry, University of Glasgow, Alexandra Parade, Glasgow, Scotland. 6th LASSA Symposium, Durban South Africa. April 2-4, 2000.
2. Use of gradient gel electrophoresis (GGE) to investigate lipoprotein particle size in apo-E knock-out mice expressing variable levels of lipoprotein lipase. S Clee 1, HE Henderson2, BD Ratanjee 3, MR Hayden1 AD Marais3. 1 Medical Genetics, Univ British Columbia, 2 Chemical Pathology and 3 Internal Medicine, Univ of Cape Town. 6th LASSA Symposium, Durban South Africa. April 2-4, 2000.
3. Modified Chugaev reaction for the derivation of cholesterol in lipoprotein fractions: a pilot study. AD Marais1, P Byrnes1, N Purdie2. 1 Internal Medicine, Univ Cape Town Health Science Faculty, 2 Chemistry Department, Oklahoma State University, Stillwaters, OK,USA..6th LASSA Symposium, Durban South Africa. April 2-4, 2000.
4. Lipid oxidation in edible oils: an evaluation using three spectrophotometric methods. D. M. Blackhurst, A.D.Marais. Lipid Laboratory, Cape Heart Centre, Health Science Faculty, University of Cape Town, Observatory, 7925 South Africa. 6th LASSA Symposium, Durban South Africa. April 2-4, 2000.
5. Efficacy of Dietary Modification in Children with Familial Hypercholesterolaemia (FH). CA Fuller, JC Firth, K H Wolmarans, P Byrnes, RM Jooste, AD Marais. Lipid Laboratory, Internal Medicine, Health Science Faculty, University of Cape Town, Observatory 7925 South Africa. 6th LASSA Symposium, Durban South Africa. April 2-4, 2000.
6. The clinical approach to dyslipidaemia in South Africa. AD Marais. Lipid laboratory, Internal medicine, Health Science Faculty, University of Cape Town, Observatory 7925 South Africa. 6th LASSA Symposium, Durban South Africa. April 2-4, 2000.
7. Electrophoretic descriptions of lipoproteins for the diagnosis of dyslipoproteinaemias. AD Marais. Lipid Laboratory, Internal Medicine, Health Science Faculty, University of Cape Town, Observatory 7925 South Africa. 6th LASSA Symposium, Durban South Africa. April 2-4, 2000.
8. The use of gradient gel electrophoresis (GGE) to investigate lipoprotein particle size variation in apoE knockout mice expressing varying levels of lipoprotein lipase (LPL). Henderson HE, Clee S, Ratanjee BD, Hayden MR, Marais AD. Division of Pathology Research Day 29 March 2000.
9. Fluvastatin in heterozygous familial hypercholesterolaemia. Firth JC, Marais AD, Byrnes P, Fuller CA, Bonnici F. 35th Annual General Meeting of Association of European Paediatric Cardiology. Strasbourg, France. June 14-17, 2000.
10. Fluvastatin extended-release formulation is effective in treating primary hypercholesterolaemia. Insull W, Marais AD, Aronson R, Manfreda S. XII ISA, Stockholm, Sweden. June 25-29, 2000.
11. Efficacy and safety of cerivastatin 0.8mg versus pravastatin 40mg for treatment of dyslipidaemia. Rubinstein A, Marais AD, Szostak WB, Colquhoun D, Keber I, Werba JP, Bertolami M, Stolero D, Tal S. XII ISA, Stockholm, Sweden. June 25-29, 2000.
12. The antioxidant effect of wine on lipid oxidation in edible oils. Blackhurst DM, Marais AD. Research Day, Department of Medicine, University of Cape Town. 05 October 2000.
13. A retrospective analysis of risk factors, clinical and angiographic characteristics in young females presenting with acute coronary syndromes. Pillay T, Commerford PJ, Marais AD. South African Heart Association Congress. Stellenbosch. 26-29 November 2000

Cardiovascular Research Unit

1. Weissenstein C., Human P, Bezuidenhout D, Zilla P. GA detoxification on top of enhanced crosslinking dramatically reduces bioprosthetic tissue calcification in the rat model J Heart Valve Dis 2000; 9:230-240
2. Deutsch M, Meinhart J, Schense J, Hubbell J, Zilla P. Endothelial Cell Seeding - Revisiting the issue" J Vasc Surg 2000; 31:1265-1268
3. Smith J., Davies N, Sumpio B, Zilla P. Smooth muscle cell secretion of VEGF is upregulated by stretching Endothelium (in print)
4. Zilla P, Bezuidenhout D, Weissenstein C., van der Walt A., Dower T., Human P. High GA concentrations mitigate bioprosthetic root calcification in the sheep model Ann Thorac Surgery (in print)
5. Zilla P, Bezuidenhout D, Weissenstein C., van der Walt A, Dower T., Human P. Diamine extension of glutaraldehyde crosslinks mitigates bioprosthetic wall calcification in the sheep model J Biomed Mat Res (accepted)
6. Meinhart J, Deutsch M, Fischlein T., Howanietz N., Zilla P. Clinical autologous in vitro endothelialization of synthetic blood surfaces: experience in 153 ePTFE grafts Ann Thorac Surg (in print)
7. Trantina A, Bracher M, Human P, Zilla P. Mitigation of bioprosthetic heart valve degeneration through biocompatibility: in-vitro versus spontaneous endothelialization Biomaterials (in print)
8. Merzkirch C., Davies N, Zilla P. Engineering of vascular ingrowth matrices: Protein fragments as an alternative to peptides Anat Record (in print)
9. Human P, Zilla P. Inflammatory and Imune Processes: The neglected villain of bioprosthetic heart valve failure? J Long Term Eff Med Impl (in print)
10. A Trantina, Weissenstein C., Human P, Zilla P. Insufficient tissue crosslinking enhances potentially detrimental transanastomotic pannus ingrowth in stentless bioprosthetic heart valves Ann Thorac Surg (in print)
11. Human P, Zilla P. The possible role of immune responses in bioprosthetic heart valve failure J Heart Valve Dis (per invitation)
12. von Oppell U., Zilla P. Prosthetic heart Valves: Why biological? J Long Term Eff Med Impl (in print)
13. Deutsch M, Meinhart J, Howanietz N., Fröschl A., Heine B., Moidl R., Mendel H., Sisel A., Stuempfen A., Zilla P. The bridge graft: a new concept for infrapopliteal surgery Eur J Vasc Surg (in print)
14. Bracher M, Davies N, Simionescu D., Simionescu A., Human P, Zilla P. The role of MMPs in tissue valve degeneration J Long Term Eff Med Impl (in print)
15. Human P, Zilla P. Graft specific antibodies are implicated in bioprosthetic aortic wall calcification Stentless bioprosthetic heart valve research: sheep vs. primate model Ann Thorac Surg (in print)